These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21557326)

  • 1. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
    Gupta A; Williams BR; Hanash SM; Rawwas J
    Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells.
    Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C
    Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression.
    Liu PY; Erriquez D; Marshall GM; Tee AE; Polly P; Wong M; Liu B; Bell JL; Zhang XD; Milazzo G; Cheung BB; Fox A; Swarbrick A; Hüttelmaier S; Kavallaris M; Perini G; Mattick JS; Dinger ME; Liu T
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
    Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
    Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs.
    Haug BH; Hald ØH; Utnes P; Roth SA; Løkke C; Flægstad T; Einvik C
    Anticancer Res; 2015 May; 35(5):2521-30. PubMed ID: 25964525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
    Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
    J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.